Cell And Gene Therapy Analytics

  1. Rapid Micro Methods In QC Micro Testing: A NIBRT Perspective 5/29/2025

    Learn about some of the advanced Rapid Micro Method systems that are being adopted by biopharma companies worldwide, and how they are changing the face of QC Microbiological testing.

  2. Successful Microbial Testing And Identification 5/27/2025

    In this presentation, one of our industry-leading customers discusses how they've successfully implemented the Applied Biosystems MicroSEQ Microbial Identification System in their laboratory testing.

  3. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  4. Inside Bioprocessing: Multi-Omics 6/16/2025

    Dive into multi-omics analysis with Paul Gulde, Chengjian Tu, and Femi Egbebi. In biopharmaceutical production, meeting the unique nutrient requirements of the cells is central to achieving optimal results.

  5. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.

  6. Introducing The Applied Biosystems Resdnaseq Quantitative DNA System 11/20/2025

    Thermo Fisher Scientific's portfolio of resDNASEQ solutions is here to meet your specific needs enabling you to test for residual host cell DNA and release your biotherapeutics with confidence in safety and confidence in product quality.

  7. Leveraging dPCR r Techniques To Quantitate Lentivirus Particles 5/28/2025

    Discover how digital PCR can streamline lentiviral vector characterization to reduce variability and improve analytical sensitivity. Learn how this approach can help you comply with regulatory guidance.

  8. Innovations In Mycoplasma And Sterility Testing For Biopharma 5/22/2025

    In this webinar, our expert speakers will discuss the types of analytical testing that can be effectively employed in the early stages of therapeutic development and subsequently scaled to meet production challenges.

  9. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  10. Cell And Gene Therapy Innovations 5/19/2025

    This interview with a pharmaceutical analytics expert discusses key insights into advances in cell and gene therapy and the strategies used to support customers in improving their therapeutic development.